These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38027142)

  • 1. Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients.
    Zhao DT; Yan HP; Han Y; Zhang WM; Zhao Y; Liao HY
    Front Endocrinol (Lausanne); 2023; 14():1142177. PubMed ID: 38027142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.
    Bosch DE; Zen Y; Boukhar SA; Liu Y; Cheng L; Yeh MM
    Virchows Arch; 2021 Dec; 479(6):1131-1143. PubMed ID: 34414507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis.
    Liu X; Xu H; Zhan M; Niu J
    Med Sci Monit; 2019 Aug; 25():6174-6180. PubMed ID: 31420961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis.
    Minuk GY; Iliant V; Zhou N; Kaita KD; Wong SG; Peretz D; Uhanova J
    Liver Int; 2018 Jun; 38(6):1110-1116. PubMed ID: 29193593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant gallstone disease was not associated with long-term outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    Chen S; Li MQ; Li BE; Lv TT; Li SX; Shan S; Li M; Kong YY; Zhang D; Ma H; Ou XJ; You H; Duan WJ; Jia JD
    J Dig Dis; 2023; 24(6-7):419-426. PubMed ID: 37464723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
    Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
    Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    Corpechot C; Carrat F; Gaouar F; Chau F; Hirschfield G; Gulamhusein A; Montano-Loza AJ; Lytvyak E; Schramm C; Pares A; Olivas I; Eaton JE; Osman KT; Dalekos G; Gatselis N; Nevens F; Cazzagon N; Zago A; Russo FP; Abbas N; Trivedi P; Thorburn D; Saffioti F; Barkai L; Roccarina D; Calvaruso V; Fichera A; Delamarre A; Medina-Morales E; Bonder A; Patwardhan V; Rigamonti C; Carbone M; Invernizzi P; Cristoferi L; van der Meer A; de Veer R; Zigmond E; Yehezkel E; Kremer AE; Deibel A; Dumortier J; Bruns T; Große K; Pageaux GP; Wetten A; Dyson J; Jones D; Chazouillères O; Hansen B; de Lédinghen V;
    J Hepatol; 2022 Dec; 77(6):1545-1553. PubMed ID: 35777587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Albumin-Bilirubin Score as a Predictor of Liver-Related Mortality in Primary Biliary Cholangitis with Compensated Cirrhosis.
    Chen Q; Zhong R; Wang Y; Kui Y; Wen X; Huang J; Jin Q
    Dig Dis; 2023; 41(6):946-956. PubMed ID: 37321186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of primary biliary cholangitis on non-alcoholic fatty liver disease.
    Iluz-Freundlich D; Uhanova J; Grubert Van Iderstine M; Minuk GY
    Eur J Gastroenterol Hepatol; 2021 Apr; 33(4):565-570. PubMed ID: 32541239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for cancer in patients with primary biliary cholangitis and autoimmune hepatitis and primary biliary cholangitis overlap syndrome.
    Braga MH; Cançado GGL; Bittencourt PL; Couto CA; Guedes LV; Lima AMC; Ferraz MLG; Villela-Nogueira CA; Nardelli MJ; Faria LC; Gomes NMF; Oliveira EMG; Rotman V; Oliveira MB; da Cunha SMCF; Cunha-Silva M; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; Pace FHL; Pessoa MG; Signorelli IV; Coral GP; Filho JG; Chagas AL; Terrabuio DRB; Cançado ELR;
    Ann Hepatol; 2023; 28(4):101105. PubMed ID: 37088418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis.
    Cheng C; Wang Z; Wang L; Zhao J; Wang Q; Tian X; Li M; Zeng X
    Clin Rheumatol; 2021 May; 40(5):1819-1826. PubMed ID: 33067770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece.
    Gatselis NK; Zachou K; Lygoura V; Azariadis K; Arvaniti P; Spyrou E; Papadamou G; Koukoulis GK; Dalekos GN; Rigopoulou EI
    Eur J Intern Med; 2017 Jul; 42():81-88. PubMed ID: 28535947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive Evaluation of Fibrosis and Portal Hypertension in Primary Biliary Cholangitis.
    Corpechot C
    Clin Liver Dis; 2022 Nov; 26(4):681-689. PubMed ID: 36270723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory risk factors for coexistent primary biliary cholangitis in patients with Sjögren's syndrome: a retrospective study.
    Gao X; Xiao G; Yang F; Dou R; Xue M; Zhang Y; Zheng Z; Ding J
    BMC Gastroenterol; 2023 Jun; 23(1):220. PubMed ID: 37365494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying Patients With Primary Biliary Cholangitis and Cirrhosis Using Administrative Data in a National Cohort.
    John BV; Bastaich D; Dahman B;
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70013. PubMed ID: 39415072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
    Kasmari AJ; Welch A; Liu G; Leslie D; McGarrity T; Riley T
    Am J Med; 2017 Jun; 130(6):746.e1-746.e7. PubMed ID: 28109969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of autoimmune, cholestatic and nonalcoholic fatty liver disease in celiac disease.
    Hitawala AA; Almomani A; Onwuzo S; Boustany A; Kumar P; Asaad I
    Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):1030-1036. PubMed ID: 37395201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis.
    Hayashi M; Abe K; Sugaya T; Takahata Y; Fujita M; Takahashi A; Ohira H
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2069-2076. PubMed ID: 38816894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.
    John BV; Dahman B; Deng Y; Khakoo NS; Taddei TH; Kaplan DE; Levy C
    Liver Int; 2022 Feb; 42(2):384-393. PubMed ID: 34614294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.